Search results for "Leukotriene receptor"

showing 6 items of 6 documents

Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cet…

2001

Background The cause and pathogenesis of chronic urticaria are still poorly understood. IgE-independent reactions, are common in adult patients with chronic urticaria, who have daily spontaneous occurrence of weals. H1-receptor antagonists (antihistamines) are the major class of therapeutic agents used in the management of urticaria and angioedema. Nevertheless, chronic urticaria is often difficult to treat and may not be controlled by antihistamines alone. It has been postulated that mediators other than histamine, such as kinins, prostaglandin and leukotrienes, may be responsible for some of the symptoms in urticaria which are not controlled by antihistamines. In this study, which was ran…

AdultCyclopropanesMalemedicine.medical_specialtyAdolescentUrticariaImmunologyAcetatesSulfidesPlaceboGastroenterologyDouble-Blind Methodimmune system diseasesInternal medicinemedicineImmunology and AllergyHumansskin and connective tissue diseasesAdverse effectMontelukastAgedLeukotrieneAngioedemaAspirinLeukotriene receptorbusiness.industryIncidenceMiddle Agedmedicine.diseaseCetirizineCetirizineFood intoleranceTreatment OutcomeItalyImmunologyChronic DiseaseHistamine H1 AntagonistsQuinolinesLeukotriene AntagonistsFemaleFood AdditivesSleep Stagesmedicine.symptombusinessFood Hypersensitivitymedicine.drugClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct

Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for…

2004

BACKGROUND: H 1 -receptor antagonists are considered to be particularly effective in reducing pruritus, and they are therefore recommended as first-line treatment in patients with chronic idiopathic urticaria (CIU). Recently, antileukotriene receptors have been used in patients with CIU, either administered as monotherapy or combined with H 1 -receptor antagonists. OBJECTIVE: We compared the clinical efficacy of 5 mg of desloratadine administered once daily either as monotherapy or combined with a leukotriene antagonist, 10 mg of montelukast daily, and 10 mg of montelukast administered daily as monotherapy for the treatment of patients affected by CIU with placebo. METHODS: One hundred sixt…

AdultCyclopropanesMalemedicine.medical_specialtyHistamine H1 Antagonists Non-SedatingSettore MED/09 - Medicina InternaAdolescentUrticariamedicine.medical_treatmentImmunologyPlacebo-controlled studyRandomized placebo-controlled trial; desloratadine; montelukast; chronic idiopathic urticariaAcetatesSulfidesPlaceboGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineImmunology and AllergyHumansMontelukastAgedDesloratadineLeukotriene E4Leukotriene receptorbusiness.industrydesloratadineRandomized placebo-controlled trialLoratadineMiddle AgedAntileukotrieneTreatment OutcomechemistryAnesthesiachronic idiopathic urticariaChronic DiseasemontelukastQuinolinesLeukotriene AntagonistsFemalebusinessmedicine.drug
researchProduct

Effects of exercise training and montelukast in children with mild asthma

2008

Data from the general population suggest that habitual exercise decreases bronchial responsiveness, but the possible role of exercise in asthmatics is undefined. The leukotriene receptor antagonist montelukast decreases bronchial responsiveness and exercise-induced symptoms in asthmatic children. This randomized study in children with mild asthma evaluated the combined effects of aerobic training for 12 wk and montelukast or placebo on bronchial responsiveness (BHR) to methacholine, exercise-induced bronchoconstriction (EIB), inflammatory markers in exhaled breath condensate (EBC), and asthma exacerbations.Fifty children (mean age +/- SD: 10.2 +/- 2.4 yr) with mild stable asthma were random…

CyclopropanesMaleQuinolineAcetatesSettore BIO/09 - Fisiologiaimmune system diseasesMedicineOrthopedics and Sports MedicineAnti-Asthmatic AgentsChildMethacholine ChlorideLeukotrieneeducation.field_of_studyrespiratory systemExercise TherapyAsthma Exercise-InducedBreath TestsItalyExhalationAnesthesiaQuinolinesFemalemedicine.drugHumanmedicine.medical_specialtyBreath TestBronchoconstrictionPopulationPhysical Therapy Sports Therapy and RehabilitationPhysical exerciseSulfidesSettore MED/10 - Malattie Dell'Apparato RespiratorioInternal medicineAerobic exerciseHumansAnti-Asthmatic AgenteducationMontelukastAsthmabusiness.industryLeukotriene receptorAcetateBronchospirometrymedicine.diseaseAsthmarespiratory tract diseasesPhysical FitnessPhysical FitneExercise TestMethacholinebusiness
researchProduct

Effects of inhaled corticosteroids, leukotriene receptor antagonists, or both, plus long-acting beta2-agonists on asthma pathophysiology: a review of…

2004

Chronic inflammation and smooth muscle dysfunction are consistent features of asthma, and are responsible for disease progression and airway remodelling. The development of chronic airway inflammation depends upon the recruitment and activation of inflammatory cells and the subsequent release of inflammatory mediators, including cytokines. Cellular and histological evaluation of drugs with anti-inflammatory activity, such as inhaled corticosteroids (ICSs), is achieved by analysing samples of lung tissue or biological fluids, obtained by techniques such as bronchial biopsy, bronchoalveolar lavage and sputum induction. These provide valuable information on the inflammatory processes occurring…

Pathophysiology of asthmamedicine.drug_classInflammationAdrenal Cortex HormonesBronchodilatorAdministration InhalationmedicineHumansPharmacology (medical)Adrenergic beta-2 Receptor AgonistsAsthmaLungmedicine.diagnostic_testLeukotriene receptorbusiness.industryNebulizers and Vaporizersmedicine.diseaseAsthmarespiratory tract diseasesmedicine.anatomical_structureBronchoalveolar lavageDelayed-Action PreparationsImmunologyLeukotriene AntagonistsBronchoconstrictionDrug Therapy CombinationReceptors Adrenergic beta-2medicine.symptombusinessDrugs
researchProduct

Leukotriene receptor antagonists in monotherapy or in combination with antihistamines in the treatment of chronic urticaria: A systematic review

2008

In vitro and in vivo clinical and experimental data have suggested that leukotrienes play a key role in inflammatory reactions of the skin. Antileukotriene drugs, ie, leukotriene receptor antagonists and synthesis inhibitors, are a class of anti-inflammatory drugs that have shown clinical efficacy in the management of asthma and in rhinitis with asthma. We searched MEDLINE database and carried out a manual search on journals specializing in allergy and dermatology for the use of antileukotriene drugs in urticaria. Montelukast might be effective in chronic urticaria associated with aspirin (ASA) or food additive hypersensitivity or with autoreactivity to intradermal serum injection (ASST) wh…

Pulmonary and Respiratory MedicineAllergyzafirlukastmedicine.medical_treatmentleukotrienes anti-inflammatory drugsReviewCold urticariaantihistamineimmune system diseasesparasitic diseasesImmunology and AllergyMedicineZafirlukastVibratory angioedemaskin and connective tissue diseasesMontelukastbusiness.industryleukotriene receptor antagonistsZileutonmedicine.diseaseAntileukotrienechronic idiopathic urticariamontelukastImmunologyAntihistaminebusinessmedicine.drug
researchProduct

One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β2-agonist in UK p…

2020

Abstract Introduction Global Initiative for Asthma (GINA) recommends medium- or high-dose inhaled corticosteroid-long-acting β2-agonist (ICS-LABA) as preferred treatments for patients with moderate-to-severe asthma. Limited data is available on how step 4/5 patients respond to ICS-LABA and how they step up/down in clinical practice. Methods This retrospective cohort study assessed the characteristics, control status, treatment pathways, and healthcare resource utilization in patients with asthma during one year after initiating medium- or high-dose ICS-LABA. Data from the United Kingdom Clinical Practice Research Datalink were analysed between January 01, 2006 and February 28, 2016. Results…

Pulmonary and Respiratory Medicinemedicine.medical_specialtybiologymedicine.drug_classLeukotriene receptorbusiness.industryAntagonistMuscarinic antagonistRetrospective cohort studyLamamedicine.diseasebiology.organism_classification03 medical and health sciences0302 clinical medicine030228 respiratory systemInternal medicineCohortmedicineCorticosteroid030212 general & internal medicinebusinessAsthmamedicine.drugRespiratory Medicine
researchProduct